Federal Trade Commission accuses three drug middlemen of inflating insulin prices
In a lawsuit, the FTC accused Optum Rx, Caremark and Express Scripts of creating "a broken rebate system that inflated insulin drug prices, boosting PBM (prescription drug benefit managers) profits at the expense of vulnerable patients.
The federal government is suing some big pharmacy benefit managers over a system of drug rebates that regulators say has made ...
The Federal Trade Commission is suing the titans of the pharmacy benefit manager industry for anticompetitive practices and ...
Millions of Americans with diabetes need insulin to survive, yet for many of these vulnerable patients, their insulin drug ...
Three companies that process about 80% of prescriptions in the United States — Caremark, Express Scripts and OptumRx — have ...
The Federal Trade Commission (FTC) filed a lawsuit Friday against three major prescription drug benefit managers (PBMs) and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback